P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism

Li, S., Fu, J., Liu, G., Ma, H., Mapara, M., Marcireau, C., & Lentzsch, S. (2023). P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism. Clinical Lymphoma Myeloma and Leukemia, 23, S145–S146. https://doi.org/10.1016/s2152-2650(23)01818-9
Authors:
Shirong Li
Jing Fu
Guifen Liu
Huihui Ma
Markus Y. Mapara
Christophe Marcireau
Suzanne Lentzsch
Affiliated Authors:
Shirong Li
Jing Fu
Guifen Liu
Huihui Ma
Suzanne Lentzsch
Publication Type:
Article
Unique ID:
10.1016/s2152-2650(23)01818-9
Publication Date:
Data Source:
OpenAlex

Record Created: